Tiziana Life Sciences Ltd (TLSA)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

Top line data readout expected in late Q3/early Q4INFORM-MS trial is a randomized, double-blind...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a...

Form 3 - Initial statement of beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form NT 20-F - Notification of inability to timely file Form 20-F